— Why it moved
Why INO Stock Spiked and Faded Today — November 2, 2026
Inovio Pharmaceuticals got FDA accelerated approval for its DNA immunotherapy, but the premarket spike quickly dissolved into a classic sell-the-news chop.
What moved INO stock
Inovio Pharmaceuticals is a clinical-stage biotech focused on DNA immunotherapies. The catalyst was real: the FDA granted accelerated approval for its drug VOCERYQ to treat a rare respiratory condition. That announcement hit over the weekend, setting off heavy premarket volume.
The mechanics
The stock gapped up 237% from Friday's close with a float near 96 million shares. Over 221 million shares traded hands as retail momentum turned a small-cap biotech into an exit ramp for legacy holders.
INO by the numbers
The alert window
The alert hit at $2.02 at 7:00 AM. Traders sat through a brief dip to $1.95 before the price pushed to $2.40 at 8:03 AM. That gave a 63-minute window for an 18.8% spike before the move ran out of steam.
How INO's move ended
Once the opening bell rang, buying interest crumbled. The stock spent 243 minutes above the alert level before fading out to close down 5.9% at $1.90. Regulatory milestones do not magically fix commercial execution risks or ongoing cash burn.
The tell: Weekend FDA approvals frequently peak in early premarket when thin liquidity allows retail chasers to mark up the price.